secwatch.observer — SEC 8-K summary
======================================

Issuer:     Taysha Gene Therapies, Inc. (TSHA)
CIK:        0001806310
Form:       8-K
Filed at:   2024-03-19T23:59:59+00:00
Accession:  0001193125-24-071321
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Taysha reports 2023 net loss of $111.6M; TSHA-102 shows sustained improvements in Rett patients
--------------------------------------------------------------------------------

- Revenue of $15.5M for full-year 2023 (up from $2.5M in 2022) from Astellas option agreement.
- Net loss of $111.6M ($0.96 loss per basic share) vs. $166.0M ($3.78/share) in 2022; includes $34.5M non-cash warrant expense.
- Cash and equivalents of $143.9M as of Dec 31, 2023; cash runway expected into 2026.
- TSHA-102 low dose (5.7x10^14 vg) in REVEAL adult trial: well-tolerated, no SAEs; patient 1 shows improved sitting, sleep, social interaction at week 35; patient 2 shows reduced seizures at week 19.
- IDMC approved early dose escalation to high dose (1x10^15 vg) in adult/pediatric trials; initial pediatric low-dose data due mid-2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806310/000119312524071321/0001193125-24-071321-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806310/000119312524071321/d790281d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-071321

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer